HN2001000266A - Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis. - Google Patents

Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis.

Info

Publication number
HN2001000266A
HN2001000266A HN2001000266A HN2001000266A HN2001000266A HN 2001000266 A HN2001000266 A HN 2001000266A HN 2001000266 A HN2001000266 A HN 2001000266A HN 2001000266 A HN2001000266 A HN 2001000266A HN 2001000266 A HN2001000266 A HN 2001000266A
Authority
HN
Honduras
Prior art keywords
receptor
osteoporosis
treatment
selective agonists
selective
Prior art date
Application number
HN2001000266A
Other languages
English (en)
Inventor
Kimberly O' Keefe Cameron
Bruce Allen Lefker
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of HN2001000266A publication Critical patent/HN2001000266A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

EL PRESENTE INVENTO SE REFIERE A AGONISTAS DE PROSTAGLANDINAS SELECTIVOS PARA EL RECEPTOR EP4, A COMBINACIONES, A PROCEDIMIENTOS, A ESTUCHES Y A COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN DICHOS AGONISTAS DE PROSTAGLANDINAS.
HN2001000266A 2000-11-27 2001-11-23 Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis. HN2001000266A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25327500P 2000-11-27 2000-11-27

Publications (1)

Publication Number Publication Date
HN2001000266A true HN2001000266A (es) 2002-01-30

Family

ID=22959588

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2001000266A HN2001000266A (es) 2000-11-27 2001-11-23 Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis.

Country Status (41)

Country Link
US (3) US6552067B2 (es)
EP (1) EP1339678B1 (es)
JP (2) JP3984164B2 (es)
KR (1) KR20030053063A (es)
CN (1) CN1476429A (es)
AR (1) AR035074A1 (es)
AT (1) ATE374182T1 (es)
AU (1) AU2002210848A1 (es)
BG (1) BG107697A (es)
BR (1) BR0115687A (es)
CA (1) CA2429850C (es)
CY (1) CY1106976T1 (es)
CZ (1) CZ20031257A3 (es)
DE (1) DE60130675T2 (es)
DK (1) DK1339678T3 (es)
EA (1) EA200300379A1 (es)
EC (1) ECSP034623A (es)
EE (1) EE200300246A (es)
ES (1) ES2291361T3 (es)
GT (2) GT200100238AA (es)
HN (1) HN2001000266A (es)
HU (1) HUP0400807A2 (es)
IL (1) IL155368A0 (es)
IS (1) IS6775A (es)
MA (1) MA26961A1 (es)
MX (1) MXPA03004623A (es)
NO (1) NO20032360L (es)
NZ (1) NZ525164A (es)
OA (1) OA12533A (es)
PA (1) PA8533901A1 (es)
PE (1) PE20020637A1 (es)
PL (1) PL362030A1 (es)
PT (1) PT1339678E (es)
SI (1) SI1339678T1 (es)
SK (1) SK5562003A3 (es)
SV (1) SV2003000746A (es)
TN (1) TNSN01166A1 (es)
TW (1) TW200424170A (es)
UY (1) UY27038A1 (es)
WO (1) WO2002042268A2 (es)
ZA (1) ZA200302803B (es)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2429850C (en) * 2000-11-27 2008-12-30 Pfizer Products Inc. Ep4 receptor selective agonists in the treatment of osteoporosis
KR20040015364A (ko) * 2001-07-16 2004-02-18 에프. 호프만-라 로슈 아게 Ｅｐ4 수용체 작용물질로서의 프로스타글란딘 유사체
BR0211167A (pt) * 2001-07-16 2004-08-10 Hoffmann La Roche Derivados de 2-pirrolidona como agonistas de prostanóides
MXPA04000757A (es) 2001-07-23 2004-07-08 Ono Pharmaceutical Co Remedios para enfermedades con perdida de masa de hueso que tienen agonistas ep4 como ingrediente activo.
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
JP4547912B2 (ja) 2002-03-05 2010-09-22 小野薬品工業株式会社 ８−アザプロスタグランジン誘導体化合物およびその化合物を有効成分として含有する薬剤
JP2005531516A (ja) * 2002-03-18 2005-10-20 ファイザー・プロダクツ・インク 選択的ｅｐ４受容体アゴニストによる治療方法
WO2003077908A1 (en) * 2002-03-18 2003-09-25 Pfizer Products Inc. Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
US6573294B1 (en) 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
EP1513589B1 (en) 2002-06-06 2010-11-10 Merck Frosst Canada Ltd. 1,5-disubstituted pyrrolid-2-one derivatives for use as ep4 receptor agonists in the treatment of eye diseases such as glaucoma
JP2005534653A (ja) * 2002-06-06 2005-11-17 メルク フロスト カナダ アンド カンパニー 眼及び骨疾患の治療に於いてｅｐ４受容体作動薬として使用するための１，５−二置換イミダゾリジン−２−オン誘導体
EP1556347A4 (en) * 2002-06-10 2006-08-09 Applied Research Systems GAMMA LACTAME AS PROSTAGLAND INAGONISTS AND THEIR USE
GB0219143D0 (en) * 2002-08-16 2002-09-25 Univ Leicester Modified tailed oligonucleotides
JP4497320B2 (ja) 2002-10-10 2010-07-07 小野薬品工業株式会社 内因性修復因子産生促進剤
WO2004037813A1 (en) * 2002-10-25 2004-05-06 Merck Frosst Canada & Co. Pyrrolidin-2-on derivatives as ep4 receptor agonists
US7528163B2 (en) 2002-11-08 2009-05-05 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US7196082B2 (en) 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US7053085B2 (en) * 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
CA2511255C (en) * 2003-01-10 2009-04-07 F. Hoffmann-La Roche Ag 2-piperidone derivatives as prostaglandin agonists
WO2004065365A1 (ja) * 2003-01-21 2004-08-05 Ono Pharmaceutical Co., Ltd. ８−アザプロスタグランジン誘導体およびその医薬用途
JP4662926B2 (ja) 2003-03-03 2011-03-30 メルク セローノ ソシエテ アノニム プロスタグランジン作動薬としてのγ−ラクタム誘導体
US6734206B1 (en) 2003-06-02 2004-05-11 Allergan, Inc. 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure
US6734201B1 (en) 2003-06-02 2004-05-11 Allergan, Inc. 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents
WO2005012232A2 (en) 2003-07-18 2005-02-10 Applied Research Systems Ars Holding N.V. Hydrazide derivatives as prostaglandin receptors modulators
US7034051B2 (en) * 2003-08-28 2006-04-25 Adolor Corporation Fused bicyclic carboxamide derivatives and methods of their use
US7576122B2 (en) 2003-09-02 2009-08-18 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
CN1845904A (zh) 2003-09-04 2006-10-11 默克公司 用于治疗高眼压的眼用组合物
JP2007504236A (ja) 2003-09-04 2007-03-01 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧症を治療するための眼用組成物
WO2005027931A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist
BRPI0417621A (pt) * 2003-12-17 2007-04-10 Pfizer Prod Inc terapia de combinação contìnua com agonistas seletivos do receptor ep4 de prostaglandina e um estrogênio para o tratamento de estados que se apresentem com baixa massa óssea
US7169807B2 (en) * 2004-04-09 2007-01-30 Allergan, Inc. 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
AU2005274972A1 (en) 2004-07-20 2006-02-23 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
WO2006043655A1 (ja) 2004-10-22 2006-04-27 Ono Pharmaceutical Co., Ltd. 吸入用医薬組成物
AU2005299473B2 (en) * 2004-10-26 2012-06-28 Allergan, Inc. Therapeutic and delivery methods of prostaglandin EP4 agonists
WO2006052630A1 (en) * 2004-11-04 2006-05-18 Allergan, Inc. Therapeutic substituted piperidone compounds
WO2006052893A2 (en) 2004-11-08 2006-05-18 Allergan, Inc. Substituted pyrrolidone compounds as ep4 agonists
US7101906B2 (en) * 2004-11-16 2006-09-05 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
US7183324B2 (en) 2004-11-23 2007-02-27 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
US7531533B2 (en) 2005-01-27 2009-05-12 Asahi Kasei Pharma Corporation 6-Membered heterocyclic compound and use thereof
AU2006209543B2 (en) * 2005-01-27 2009-04-30 Asahi Kasei Pharma Corporation Six-membered heterocyclic compound and the use thereof
US7772392B2 (en) 2005-05-06 2010-08-10 Allergan, Inc. Therapeutic substituted β-lactams
JP5254007B2 (ja) * 2005-05-06 2013-08-07 アラーガン インコーポレイテッド 置換β−ラクタム及び医薬におけるその使用
US7893107B2 (en) 2005-11-30 2011-02-22 Allergan, Inc. Therapeutic methods using prostaglandin EP4 agonist components
KR100598678B1 (ko) * 2006-02-15 2006-07-19 (주)아이앤씨 수직형 대형 폐기물 파쇄기
US20070232660A1 (en) * 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
US9394520B2 (en) 2006-12-08 2016-07-19 University Of Rochester Expansion of hematopoietic stem cells
EP2548559A1 (en) 2006-12-18 2013-01-23 Allergan, Inc. Methods and compositions for treating gastrointestinal disorders
AU2008246579A1 (en) 2007-05-08 2008-11-13 National University Corporation, Hamamatsu University School Of Medicine Cytotoxic T cell activator comprising EP4 agonist
ES2395875T3 (es) * 2007-05-23 2013-02-15 Allergan, Inc. Lactamas cíclicas para el tratamiento del glaucoma o de la presión intraocular elevada
US8063033B2 (en) * 2008-01-18 2011-11-22 Allergan, Inc. Therapeutic beta-lactams
US8202855B2 (en) 2008-03-04 2012-06-19 Allergan, Inc Substituted beta-lactams
US7705001B2 (en) * 2008-03-18 2010-04-27 Allergan, Inc Therapeutic substituted gamma lactams
JP5536773B2 (ja) * 2008-08-14 2014-07-02 ベータ・ファーマ・カナダ・インコーポレイテッド Ｅｐ４受容体アンタゴニストとしてのヘテロ環式アミド誘導体
WO2010116270A1 (en) 2009-04-10 2010-10-14 Pfizer Inc. Ep2/4 agonists
KR20120093955A (ko) 2009-10-14 2012-08-23 젬머스 파마 인코포레이티드 바이러스 감염에 대한 병용 요법 치료
WO2011111714A1 (ja) * 2010-03-08 2011-09-15 科研製薬株式会社 新規なｅｐ４アゴニスト
CA2738045C (en) 2010-05-28 2019-02-19 Simon Fraser University Conjugate compounds, methods of making same, and uses thereof
EP2397141A1 (en) * 2010-06-16 2011-12-21 LEK Pharmaceuticals d.d. Process for the synthesis of beta-amino acids and derivatives thereof
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
AU2012217630A1 (en) 2011-02-17 2013-09-05 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2678022A2 (en) 2011-02-23 2014-01-01 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2013123272A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2814526B1 (en) 2012-02-16 2016-11-02 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2814482A1 (en) 2012-02-16 2014-12-24 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2013123275A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
CA2879506C (en) 2012-07-19 2020-10-27 Cayman Chemical Company, Inc. Difluorolactam compositions for ep4-mediated osteo related diseases and conditions
ES2733998T3 (es) 2012-10-29 2019-12-03 Cardio Incorporated Agente terapéutico específico de enfermedad pulmonar
US9676712B2 (en) 2013-03-15 2017-06-13 Cayman Chemical Company, Inc. Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
CA2903314C (en) 2013-03-15 2023-02-14 Cayman Chemical Company, Inc. Methods of synthesizing a difluorolactam analog
EA201591793A1 (ru) * 2013-03-15 2016-01-29 Кайман Кемикал Компани, Инк. Лактамные соединения в качестве селективных агонистов ep4-рецепторов для применения при лечении опосредованных ep4 заболеваний и состояний
EP3021879A2 (en) 2013-07-19 2016-05-25 Cayman Chemical Company, Incorporated Methods, systems, and compositions for promoting bone growth
IL280864B2 (en) 2013-08-09 2024-03-01 Ardelyx Inc Compounds and methods for inhibiting phosphate transport
WO2015056504A1 (ja) 2013-10-15 2015-04-23 小野薬品工業株式会社 薬剤溶出性ステントグラフト
US9650414B1 (en) 2014-05-30 2017-05-16 Simon Fraser University Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof
KR20170010059A (ko) 2014-06-06 2017-01-25 알러간, 인코포레이티드 치료적 화합물로서 신규한 ep4 작용제
US9540357B1 (en) 2014-07-31 2017-01-10 Allergan, Inc. 15-aryl prostaglandins as EP4 agonists, and methods of use thereof
JP7174982B2 (ja) 2015-06-12 2022-11-18 サイモン フレイザー ユニヴァーシティー アミド連結ｅｐ４アゴニスト－ビスホスホネート化合物およびその使用
CN107011377B (zh) * 2017-05-03 2019-02-26 南通书创药业科技有限公司 一种β-羰基磷酸酯的制备方法
EP3733665B1 (en) * 2017-12-25 2022-09-28 Asahi Kasei Pharma Corporation 2-oxo-1,3,4-thiadiazinan-3-yl moiety containing compounds with ep4 receptor agonist activity
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1158163A (en) 1966-06-15 1969-07-16 Berk Ltd Improvements in or relating to Polymer Compositions
ZA72645B (en) * 1971-03-05 1972-11-29 Upjohn Co Prostaglandin analogs
DE2346706A1 (de) * 1973-09-17 1975-04-03 Hoechst Ag Neue, nicht natuerlich vorkommende analoga von prostansaeuren und verfahren zu ihrer herstellung
US3975399A (en) 1974-08-06 1976-08-17 E. I. Du Pont De Nemours And Company 1,5-Disubstituted-2-pyrrolidinones, -3-pyrrolin-2-ones, and -4-pyrrolin-2-ones
US4113873A (en) 1975-04-26 1978-09-12 Tanabe Seiyaku Co. Ltd. 8-azaprostanoic acid derivatives
NL7604330A (nl) 1975-04-28 1976-11-01 Syntex Inc Werkwijze voor de bereiding van 8-azaprostaan- zuurderivaten.
DE2528664A1 (de) 1975-06-27 1977-01-13 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
IL49325A (en) 1976-03-31 1979-11-30 Labaz 8-aza-11-deoxy-pge1 derivatives,their preparation and pharmaceutical compositions containing them
DE2619638A1 (de) 1976-05-04 1977-11-17 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
CA1077948A (en) * 1976-08-06 1980-05-20 Albin J. Nelson 1,-5 disubstituted-2-pyrrolidones and processes for their production
US4177346A (en) * 1976-08-06 1979-12-04 Pfizer Inc. 1,5-Disubstituted-2-pyrrolidones
US4320136A (en) 1980-08-11 1982-03-16 E. I. Du Pont De Nemours And Company 8-Aza-16,16-difluoroprostanoids
US4456613A (en) 1982-12-27 1984-06-26 E. I. Du Pont De Nemours And Company 6-Keto- and 6-hydroxy-8-azaprostanoids and anti-ulcer use thereof
TW288010B (es) 1992-03-05 1996-10-11 Pfizer
SE9302334D0 (sv) 1993-07-06 1993-07-06 Ab Astra New compounds
ZA944647B (en) 1993-07-06 1995-01-06 Astra Ab Novel (1-phenyl-1-heterocyclyl)methanol and (1-phenyl-1-heterocyclcl)methylamine derivatives
US5955481A (en) 1994-03-28 1999-09-21 Nissan Chemical Industries, Ltd. Pyridine type thiazolidines
TW420669B (en) 1994-03-28 2001-02-01 Nissan Chemical Ind Ltd Pyridine type thiazolidines
US5703108A (en) * 1996-02-28 1997-12-30 Pfizer Inc. Bone deposition by certain prostaglandin agonists
WO2000021542A1 (en) * 1998-10-15 2000-04-20 Merck & Co., Inc. Methods for stimulating bone formation
CA2346038A1 (en) 1998-10-15 2000-04-20 Merck & Co., Inc. Methods for inhibiting bone resorption
AU1293101A (en) * 1999-12-22 2001-07-03 Pfizer Products Inc. Ep4 receptor selective agonists in the treatment of osteoporosis
DK1132086T3 (da) * 2000-01-31 2006-08-28 Pfizer Prod Inc Anvendelse af prostaglandin (PGE2) selektive receptor 4 (EP4) agonister til behandling af akut og kronisk nyresvigt
US20010056060A1 (en) * 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
CA2429850C (en) * 2000-11-27 2008-12-30 Pfizer Products Inc. Ep4 receptor selective agonists in the treatment of osteoporosis
US6573294B1 (en) * 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure

Also Published As

Publication number Publication date
DK1339678T3 (da) 2008-02-04
PE20020637A1 (es) 2002-07-18
CY1106976T1 (el) 2012-09-26
IS6775A (is) 2003-04-10
ECSP034623A (es) 2003-07-25
TNSN01166A1 (fr) 2005-11-10
US20040259921A1 (en) 2004-12-23
CZ20031257A3 (cs) 2004-04-14
CA2429850C (en) 2008-12-30
HUP0400807A2 (hu) 2004-07-28
AR035074A1 (es) 2004-04-14
US7192979B2 (en) 2007-03-20
JP2007197467A (ja) 2007-08-09
ES2291361T3 (es) 2008-03-01
BG107697A (en) 2004-01-30
EP1339678A2 (en) 2003-09-03
UY27038A1 (es) 2002-07-31
NO20032360L (no) 2003-07-23
PA8533901A1 (es) 2002-11-28
CN1476429A (zh) 2004-02-18
TW200424170A (en) 2004-11-16
US20020065308A1 (en) 2002-05-30
MA26961A1 (fr) 2004-12-20
EP1339678B1 (en) 2007-09-26
US6747054B2 (en) 2004-06-08
SV2003000746A (es) 2003-01-13
WO2002042268A3 (en) 2002-07-25
SI1339678T1 (sl) 2007-12-31
NO20032360D0 (no) 2003-05-26
NZ525164A (en) 2005-04-29
DE60130675T2 (de) 2008-01-24
DE60130675D1 (de) 2007-11-08
GT200100238AA (es) 2004-05-12
BR0115687A (pt) 2003-09-09
PT1339678E (pt) 2007-11-30
ATE374182T1 (de) 2007-10-15
WO2002042268A2 (en) 2002-05-30
MXPA03004623A (es) 2003-09-05
ZA200302803B (en) 2004-04-13
EA200300379A1 (ru) 2003-08-28
IL155368A0 (en) 2003-11-23
JP2004521869A (ja) 2004-07-22
CA2429850A1 (en) 2002-05-30
SK5562003A3 (en) 2004-08-03
JP3984164B2 (ja) 2007-10-03
GT200100238A (es) 2002-06-26
PL362030A1 (en) 2004-10-18
AU2002210848A1 (en) 2002-06-03
US20030149086A1 (en) 2003-08-07
OA12533A (en) 2006-06-05
EE200300246A (et) 2003-10-15
US6552067B2 (en) 2003-04-22
KR20030053063A (ko) 2003-06-27

Similar Documents

Publication Publication Date Title
HN2001000266A (es) Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis.
DOP2012000290A (es) 4-yodo-3-nitrobenzamida en combinacion con agentes anti-tumorales para el uso en el tratamiento de cancer utero y cancer de ovario
CO5160262A1 (es) Formulaciones farmaceuticas de liberacion controlada
DOP2002000545A (es) Moléculas pequeñas para el tratamiento del crecimiento celular anormal
GT200500119A (es) Derivados de tetraazabenzo [e] azuleno y sus analogos
DOP2007000016A (es) Agentes citotoxicos que comprenden nuevos derivados de tomaimicina.
ECSP088222A (es) Agonistas de receptores adrenérgicos alfa2c funcionalmente selectivos
HN2004000319A (es) "{ 1,8}naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia"
ECSP088390A (es) Método para la anticoncepción hormonal preventiva bajo demanda
UY30905A1 (es) Composiciones para mejorar la absorcion gastrointestinal de nutrientes y farmacos
UY27188A1 (es) Uso de agonistas inversos de gabaa en combinación con agonistas parciales del receptor de nicotina, estrógenos, moduladores selectivos de estrógenos o vitamina e, para el tratamiento de trastornos cognitivos.
HN2005000255A (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
MA30765B1 (fr) Derives innovants du thiophene
CL2007002578A1 (es) Compuestos derivados de n-(1-ftalazin-1-il-piperidin-4-il)-amidas; composicion farmaceutica; y uso para el tratamiento y prevencion de trastornos de la fertilidad, osteoporosis y cancer.
CL2009000281A1 (es) Compuestos derivados de 5,6-dihidro-pirrolo-[2,1-a]-isoquinolinas y pirrolo-[2,1-a]-isoquinolinas; composicion farmaceutica que comprende a dichos compuestos; y uso para el tratamaiento de trastornos de la fertilidad.
HN2009000018A (es) Inhibidores de tirosina quinasa
PL1845957T3 (pl) Sposób uzyskiwania ekstraktu leku zawierającego hydroksystylben
GT200600157A (es) Asociacion entre la ferroquina y un derivado de artemisinina para el tratamiento del paludismo
ECSP088635A (es) Formulaciones orales que comprenden tigeciclina
AR061446A1 (es) Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico
UY28925A1 (es) Nuevos derivados de aminopiridina y su uso como fármacos
GT200200235A (es) Composiciones farmaceuticas y procedimientos para administrar agonistas selectivos del receptor ep2
PA8571901A1 (es) Nueva composicion farmaceutica
GT200500268A (es) Inhibidores de la adenilato ciclasa soluble
AR046402A1 (es) Combinacion de principio activo que comprende un compuesto 2,5-dihidrobencenosulfonico y un modulador de los canales de potasio